Our final version of human AGO2 led editing of RNA is out today in @NatureBiotech! Led by @noScandineHere, we got excited by the reduced immunogenic risk and efficacy advantages of using a human-derived protein for non-downregulatory RNA manipulation.
https://t.co/0cyURONnEH
In Brief: @FDA greenlights @ionispharma's #Zanvastro, the first disease-modifying drug for a rare, progressive and often fatal neurological condition known as Alexander disease https://t.co/fhDD4onoId
https://t.co/nwLLukhg7I
Each year, we highlight companies that received sizeable early-stage funding in the previous year. @bioptimus_ai is developing multimodal and multiscale AI pathology models for biomarker and drug treatment prediction https://t.co/81BoWojNUN
How much do PhD students earn?
The first comprehensive overview of PhD income shows vast imbalances across much of Europe
Read the full story: https://t.co/AKk2SyX5cT https://t.co/EXVWETGS6W